ÌÇÐÄvlog

[Skip to Navigation]
Sign In

October 2024 - April 2016

Decade

Year

Issue

November 2023, Vol 8, No. 11, Pages 1004-1102

Original Investigation

Fractional Flow Reserve–Negative High-Risk Plaques and Clinical Outcomes After Myocardial Infarction

Abstract Full Text
free access
JAMA Cardiol. 2023;8(11):1013-1021. doi:10.1001/jamacardio.2023.2910

This cohort study assesses the association between optical coherence tomography (OCT)-detected, fractional flow reserve (FFR)-negative nonculprit lesions and adverse cardiovascular events in patients with myocardial infarction (MI).

Long-Term Quality of Life After Out-of-Hospital Cardiac Arrest

Abstract Full Text
free access
JAMA Cardiol. 2023;8(11):1022-1030. doi:10.1001/jamacardio.2023.2934

This survey study uses standardized patient-reported outcome measures to determine the long-term quality of life of survivors of out-of-hospital cardiac arrest in Denmark.

Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial

Abstract Full Text
open access
JAMA Cardiol. 2023;8(11):1031-1040. doi:10.1001/jamacardio.2023.3003

This randomized clinical trial evaluates repurposing mirabegron, a β3-adrenergic receptor agonist, to prevent progression of left ventricular hypertrophy and diastolic dysfunction among patients with pre- or mild heart failure.

Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management

Abstract Full Text
free access
JAMA Cardiol. 2023;8(11):1041-1048. doi:10.1001/jamacardio.2023.3216

This economic evaluation examines the cost-effectiveness of sacubitril-valsartan among a range of ejection fractions and at different upper-level cutoffs of below-normal ejection fractions.

Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020

Abstract Full Text
free access has audio
JAMA Cardiol. 2023;8(11):1050-1060. doi:10.1001/jamacardio.2023.3241

This cohort study investigates the prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, using data from the National Health and Nutrition Examination Survey.

Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial

Abstract Full Text
open access
JAMA Cardiol. 2023;8(11):1061-1069. doi:10.1001/jamacardio.2023.3364

This post hoc secondary analysis of a randomized clinical trial compares the effectiveness and safety of enteric-coated aspirin vs uncoated aspirin among patients with atherosclerotic cardiovascular disease.

Brief Report

Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia

Abstract Full Text
open access
JAMA Cardiol. 2023;8(11):1070-1076. doi:10.1001/jamacardio.2023.2921

This randomized clinical trial investigates if evinacumab provides a sustained reduction in low-density lipoprotein cholesterol level in patients with hypercholesterolemia refractory to maximum-tolerated combinations of currently available lipid-lowering therapies.

The Role of Posterior Wall Isolation in Catheter Ablation for Persistent Atrial Fibrillation and Systolic Heart Failure: A Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
free access
JAMA Cardiol. 2023;8(11):1077-1082. doi:10.1001/jamacardio.2023.3208

This secondary analysis of a randomized clinical trial examines whether adding posterior wall isolation to pulmonary vein isolation improves outcomes in patients with heart failure (HF) with reduced ejection fraction and atrial fibrillation (AF).

Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial

Abstract Full Text
free access
JAMA Cardiol. 2023;8(11):1083-1088. doi:10.1001/jamacardio.2023.2808

This randomized clinical trial assesses the role of valsartan in modification of disease progression and characterizes short-term phenotypic progression among sarcomere variant carriers with subclinical hypertrophic cardiomyopathy.

Viewpoint

Is There a Need for Palliative Care for Patients With Heart Failure With Preserved Ejection Fraction?

Abstract Full Text
JAMA Cardiol. 2023;8(11):1005-1006. doi:10.1001/jamacardio.2023.3360

This Viewpoint discusses palliative care for patients with heart failure with preserved ejection fraction.

From the Heart

Tyranny of the Rules

Abstract Full Text
JAMA Cardiol. 2023;8(11):1007-1008. doi:10.1001/jamacardio.2023.3226

This essay describes the author’s experience with the application of medical guidelines in the treatment of patients.

Editorial

Reducing the Risks of Nuclear War—The Role of Health Professionals

Abstract Full Text
free access
JAMA Cardiol. 2023;8(11):1009-1010. doi:10.1001/jamacardio.2023.2889
Invited Commentary

Medical Editors vs Nuclear Weapons—Is the Pen Mightier Than the Sword?

Abstract Full Text
JAMA Cardiol. 2023;8(11):1011-1012. doi:10.1001/jamacardio.2023.2890
  • Editorial
    Reducing the Risks of Nuclear War—The Role of Health Professionals
    JAMA Cardiol

Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions

Abstract Full Text
JAMA Cardiol. 2023;8(11):1048-1049. doi:10.1001/jamacardio.2023.3223
Review

AI in Cardiology

Deep Learning for Cardiovascular Imaging: A Review

Abstract Full Text
free access has active quiz
JAMA Cardiol. 2023;8(11):1089-1098. doi:10.1001/jamacardio.2023.3142

This narrative review describes the potential for artificial intelligence applications to reduce technical burden and improve efficiency in cardiovascular imaging and explains the challenges in the development and implementation of deep learning systems.

Cardiovascular Images

Woman in Her 50s With an Intravenous Mass Extending to the Right Cardiac Chamber

Abstract Full Text
has active quiz has multimedia
JAMA Cardiol. 2023;8(11):1099. doi:10.1001/jamacardio.2023.3385

This case report describes a diagnosis of intravenous leiomyomatosis in a woman in her 50s who presented with exertional dyspnea and syncope and had a history of hysteromyomectomy.

Comment & Response

Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction

Abstract Full Text
JAMA Cardiol. 2023;8(11):1100. doi:10.1001/jamacardio.2023.3571

Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction

Abstract Full Text
JAMA Cardiol. 2023;8(11):1100-1101. doi:10.1001/jamacardio.2023.3574

Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction—Reply

Abstract Full Text
JAMA Cardiol. 2023;8(11):1101-1102. doi:10.1001/jamacardio.2023.3577
Correction

Error in Author Name

Abstract Full Text
free access
JAMA Cardiol. 2023;8(11):1102. doi:10.1001/jamacardio.2023.4242
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2023;8(11):1004. doi:10.1001/jamacardio.2022.3460
×